Using this approach, we report that the BDP1 alterations identified in ovarian cancer were deep deletions with decreased expression correlating with increased serous ovarian cancer stage similar to known critical cancer drivers, BRCA1 and BRCA2. This evidence concerns the gene BRCA1 and ovarian serous adenocarcinoma.